Drug Profile


Alternative Names: SAF302

Latest Information Update: 27 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LYSOGENE
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis III
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Mucopolysaccharidosis III

Most Recent Events

  • 22 Dec 2017 LYSOGENE plans to initiate a pivotal clinical trial in Mucopolysaccharidosis III in first half of 2018
  • 19 Sep 2017 Lysogene reported about working on the Paediatric Investigation Plan (PIP) with the EMA
  • 31 Aug 2017 Preclinical trials in Mucopolysaccharidosis III in France (Intracerebral) (LYSOGENE pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top